LPS-Induced Neuroinflammation in Neurodegenerative Diseases: A Double-Edged Sword?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and theoretical models with no original human clinical trial or cohort data.
PubMed 42322379 · doi:10.1007/s12035-026-06004-6
What was done
This narrative review synthesized experimental literature examining lipopolysaccharide (LPS)-induced Toll-like receptor 4 (TLR4) signaling in microglia and astrocytes. It evaluated how exposure variables (dose, duration, administration route, host inflammatory state) and gut-brain axis interactions influence outcomes in Alzheimer's and Parkinson's disease models.
What was found
The abstract reports conceptual mechanisms without numerical data or statistical metrics. Chronic or high-dose LPS exposure leads to sustained neuroinflammation, blood-brain barrier disruption, reduced amyloid-beta clearance, and worsened alpha-synuclein pathology, whereas low-dose or intermittent exposure is associated with regulated glial signaling and enhanced neuronal resilience.
Why it matters
Framing LPS-induced neuroinflammation as a dynamic spectrum rather than purely destructive helps clarify conflicting experimental results and highlights potential therapeutic targets across TLR4 signaling, autophagy, and the gut-brain axis.
Limits
This is a narrative review without systematic search criteria or meta-analytic data. Most cited findings rely on preclinical models, leaving translation to region-specific human glial responses unverified.
Cited by
- supports Lipopolysaccharide (LPS) can cross the blood-brain barrier and activate microglial immune cells, inducing brain inflammation.